Analysis of information sources in references of the Wikipedia article "Finasteride" in English language version.
Last modified:
In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
Transgender women may request 5α-reductase inhibitors to improve the anti-androgen effects of feminizing treatment, but no clinical studies supported their use. Especially when testosterone levels are already suppressed, as seen during CPA or spironolactone treatment, the benefit of 5α-reductase inhibitors will probably be negligible. As recently discussed, testosterone levels could increase during treatment with 5α-reductase inhibitors (46, 47). We are not aware of studies in transgender women regarding the effect of 5α-reductase inhibitors on secondary female characteristics. In conclusion, treatment with 5α-reductase inhibitors in transgender women is considered to be of no clinical benefit and is, therefore, not recommended.
Finasteride, a 5-alpha-reductase-2 antagonist, reduces the conversion of testosterone to the more potent dihydrotestosterone. Although not considered useful in transgender women who have testosterone levels within the female range, it can be considered an option for those patients who have higher testosterone levels who show male pattern hair loss [5].
Finasteride is not actually an antiandrogen but a 5α-reductase inhibitor.
In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
Transgender women may request 5α-reductase inhibitors to improve the anti-androgen effects of feminizing treatment, but no clinical studies supported their use. Especially when testosterone levels are already suppressed, as seen during CPA or spironolactone treatment, the benefit of 5α-reductase inhibitors will probably be negligible. As recently discussed, testosterone levels could increase during treatment with 5α-reductase inhibitors (46, 47). We are not aware of studies in transgender women regarding the effect of 5α-reductase inhibitors on secondary female characteristics. In conclusion, treatment with 5α-reductase inhibitors in transgender women is considered to be of no clinical benefit and is, therefore, not recommended.
Finasteride, a 5-alpha-reductase-2 antagonist, reduces the conversion of testosterone to the more potent dihydrotestosterone. Although not considered useful in transgender women who have testosterone levels within the female range, it can be considered an option for those patients who have higher testosterone levels who show male pattern hair loss [5].
these legal briefs filed by plaintiffs' lawyers allege that in revisions to the drug's original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.
In studies addressing reversibility, most of these patients have resolution of sexual adverse effects after discontinuation of finasteride, and many have improvement of adverse effects over time with continued finasteride use. However, some studies describe a subset of patients with persistent adverse effects after discontinuation... Level 1 evidence evaluating sexual dysfunction as a primary outcome was available for finasteride.
{{cite web}}: CS1 maint: bot: original URL status unknown (link)these legal briefs filed by plaintiffs' lawyers allege that in revisions to the drug's original 1997 label, Merck understated the number of men who experienced sexual symptoms in clinical trials, and how long those symptoms lasted.